

BIOCON GROUP

FACT SHEET

June - 2016

BIOCON LIMITED (CONSOLIDATED)
PROFIT & LOSS STATEMENT

(Rs. Cr)

Particulars	Q1 - F17			Q1 - F16			Variance IGAAP	Variance IndAS
	IGAAP	Adj	IndAS	IGAAP	Adj	IndAS		
INCOME								
Biocon	640	78	718	601	(14)	587	7%	22%
Small molecules	357	63	420	329	10	339	9%	24%
Biologics	107	16	123	70	2	72	53%	71%
Branded formulations	159	(1)	158	138	(26)	112	15%	41%
Licensing (incl capacity reservation)	17	-	17	64	-	64	-73%	-73%
Syngene - Research Services	263	-	263	224	-	224	18%	18%
Total Sales	903	78	981	825	(14)	811	10%	21%
Other income	49	1	50	32	(2)	30	52%	65%
TOTAL REVENUE	952	79	1,031	857	(16)	841	11%	23%
EXPENDITURE								
Material & Power costs	393	45	438	363	2	365	8%	20%
Staff costs	163	1	164	141	(6)	135	15%	21%
Research & Development **	52	-	52	50	-	50	4%	3%
Other expenses	73	-	73	67	(4)	63	10%	17%
Manufacturing, staff & other expenses	681	46	727	621	(8)	613	10%	19%
EBITDA	271	33	304	236	(8)	228	15%	33%
Interest & Finance charges	6	-	6	4	-	4	30%	30%
Depreciation & Amortisation	64	2	66	58	1	59	11%	12%
Share of profit in JV	(5)	-	(5)	-	(4)	(4)	-	42%
PBT	206	31	237	174	(5)	169	19%	41%
Taxes	43	11	54	37	1	38	17%	47%
NET PROFIT BEFORE MINORITY INTEREST	163	20	183	137	(6)	131	20%	39%
Minority interest	16	-	16	11	(4)	7	55%	123%
NET PROFIT FOR THE PERIOD	147	20	167	126	(2)	124	17%	34%
EPS Rs.	7.4		8.4	6.3		6.2		

Note: The figures are rounded off to the nearest crore, percentages are based on absolute numbers

* Gross Research & Development expenses

92

93

BIOCON LIMITED (CONSOLIDATED)
PROFIT & LOSS STATEMENT (Rs. Cr)

Particulars	Q1 - F17			Q4 - F16			Variance IGAAP	Variance IndAS
	IGAAP	Adj	IndAS	IGAAP	Adj	IndAS		
INCOME								
Biocon	640	78	718	654	(24)	630	-2%	14%
Small molecules	357	63	420	385	10	395	-7%	7%
Biologics	107	16	123	114	6	120	-6%	2%
Branded formulations	159	(1)	158	132	(27)	105	20%	50%
Licensing (incl capacity reservation)	17	-	17	23	(13)	10	-25%	67%
Syngene - Research Services	263	-	263	316	-	316	-17%	-17%
Total Sales	903	78	981	970	(24)	946	-7%	4%
Other income	49	1	50	34	(1)	33	46%	52%
TOTAL REVENUE	952	79	1,031	1,004	(25)	979	-5%	5%
EXPENDITURE								
Material & Power costs	393	45	438	402	5	407	-2%	8%
Staff costs	163	1	164	161	(7)	154	1%	7%
Research & Development **	52	-	52	100	-	100	-48%	-48%
Other expenses	73	-	73	103	(3)	100	-29%	-26%
Manufacturing, staff & other expenses	681	46	727	766	(5)	761	-11%	-4%
EBITDA	271	33	304	238	(20)	218	14%	39%
Interest & Finance charges	6	-	6	1	15	16	307%	-66%
Depreciation & Amortisation	64	2	66	63	2	65	2%	2%
Share of profit in JV	(5)	-	(5)	-	(5)	(5)	-	2%
PBT BEFORE EXCEPTIONAL ITEM	206	31	237	174	(32)	142	18%	67%
Exceptional item, Net	-	-	-	268	-	268	-	-
PBT	206	31	237	442	(32)	410	-53%	-42%
Taxes	43	11	54	46	1	47	-6%	18%
Taxes on exceptional item	-	-	-	12	-	12	-	-
NET PROFIT BEFORE MINORITY INTEREST	163	20	183	384	(33)	351	-58%	-48%
Minority interest	16	-	16	23	(2)	21	-30%	-25%
NET PROFIT FOR THE PERIOD	147	20	167	361	(31)	330	-59%	-50%
EPS Rs.	7.4		8.4	18.1		16.5		

Note: The figures are rounded off to the nearest crore, percentages are based on absolute numbers

* Gross Research & Development expenses

92

152